公开(公告)号：US10286018B2

公开(公告)日：2019-05-14

申请号：US15472754

申请日：2017-03-29

Applicant: Chr. Hansen A/S

Inventor： Tracey Jane Smith

IPC: A61K35/74 ,  A61K35/745 ,  A61K35/747 ,  A61K35/742

Abstract: The present invention relates to a composition comprising Lactobacillus rhamnosus, preferably strain ATCC53103, and Bifidobacterium animalis subsp. lactis, preferably strain DSM 15954, for use in reducing the duration and/or severity of upper respiratory tract infection (URI) in teenagers and adults. Further aspects of the invention relate to a composition comprising Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis for use in increasing the Health-Related Quality of Life (HRQL) in teenagers and adults having upper respiratory tract infection (URI), for reducing at least one and preferably several such as two, three, four or all of the symptoms of sore throat, scratchy throat, cough, hoarseness, chest congestion and for reducing the median severity score in teenagers and adults having upper respiratory tract infection (URI).

公开(公告)号：US20150118190A1

公开(公告)日：2015-04-30

申请号：US14371888

申请日：2013-01-14

Applicant: Chr. Hansen A/S

Inventor： Tracey Jane Smith

IPC: A61K35/745 ,  A61K35/747

CPC classification number: A61K35/745 ,  A61K35/742 ,  A61K35/747 ,  A61K2300/00

Abstract: The present invention relates to a composition comprising Lactobacillus rhamnosus, preferably strain ATCC53103, and Bifidobacterium animalis subsp. lactis, preferably strain DSM 15954, for use in reducing the duration and/or severity of upper respiratory tract infection (URI) in teenagers and adults. Further aspects of the invention relate to a composition comprising Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis for use in increasing the Health-Related Quality of Life (HRQL) in teenagers and adults having upper respiratory tract infection (URI), for reducing at least one and preferably several such as two, three, four or all of the symptoms of sore throat, scratchy throat, cough, hoarseness, chest congestion and for reducing the median severity score in teenagers and adults having upper respiratory tract infection (URI).

Abstract translation: 本发明涉及包含鼠李糖乳杆菌（Lactobacillus rhamnosus），优选菌株ATCC53103和动物双歧杆菌（Bifidobacterium animalis subsp。）的组合物。 乳酸菌，优选菌株DSM 15954，用于减少青少年和成人中上呼吸道感染（URI）的持续时间和/或严重程度。 本发明的其它方面涉及包含鼠李糖乳杆菌和动物双歧杆菌的组合物。 用于增加具有上呼吸道感染（URI）的青​​少年和成人中与健康相关的生活质量（HRQL），用于减少至少一种，优选几种，例如两种，三种，四种或全部的疼痛症状 喉咙痛，喉咙痛，咳嗽，声音嘶哑，胸部充血，以及降低青少年和上呼吸道感染（URI）成人患者的中位重度评分。

公开(公告)号：US09642883B2

公开(公告)日：2017-05-09

申请号：US14371888

申请日：2013-01-14

Applicant: Chr. Hansen A/S

Inventor： Tracey Jane Smith

IPC: A61K35/74 ,  A61K35/745 ,  A61K35/747 ,  A61K35/742

CPC classification number: A61K35/745 ,  A61K35/742 ,  A61K35/747 ,  A61K2300/00

Abstract: The present invention relates to a composition comprising Lactobacillus rhamnosus, preferably strain ATCC53103, and Bifidobacterium animalis subsp. lactis, preferably strain DSM 15954, for use in reducing the duration and/or severity of upper respiratory tract infection (URI) in teenagers and adults. Further aspects of the invention relate to a composition comprising Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis for use in increasing the Health-Related Quality of Life (HRQL) in teenagers and adults having upper respiratory tract infection (URI), for reducing at least one and preferably several such as two, three, four or all of the symptoms of sore throat, scratchy throat, cough, hoarseness, chest congestion and for reducing the median severity score in teenagers and adults having upper respiratory tract infection (URI).